Salmeterol
Selective Beta-2-Adrenoreceptor Agonists
Sold as ADVAIR · BroPair Spiromax · Aerivio Spiromax · Seffalair Spiromax · WIXELA INHUB
- Drug class
- Selective Beta-2-Adrenoreceptor Agonists
- Availability
- See label
- Routes
- Inhalation
- Markets covered
- 3
- Products on record
- 229
Overview
Salmeterol is an active pharmaceutical ingredient in the Selective Beta-2-Adrenoreceptor Agonists group (R03AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 213 | May 22, 2026 |
| CA Canada | Health Canada | 15 | March 22, 2025 |
| EU European Union | EMA | 1 | December 16, 2025 |
GBUnited Kingdom· MHRA
213 products
Uses
Not applicable
How to take
CACanada· Health Canada
15 products
Uses
Asthma SEREVENT DISKUS (salmeterol xinafoate) is indicated for the treatment of asthma only as add-on therapy to an inhaled corticosteroid; a long-term asthma control medication; in patients 4 years of age and older with reversible obstructive airway disease, including patients with nocturnal asthma.
Corticosteroids should not be stopped because salmeterol is prescribed. Long-acting beta2-adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, increase the risk of asthma-related death (see WARNINGS AND PRECAUTIONS).
Use of SEREVENT DISKUS for the treatment of asthma without concomitant use of an inhaled corticosteroid; a long-term asthma control medication; is contraindicated (see CONTRAINDICATIONS). Use SEREVENT DISKUS only as add-on therapy for patients with asthma who are currently taking but are inadequately controlled on an inhaled corticosteroid.
Once asthma control is achieved and maintained, assess the patient at regular intervals. If possible without loss of asthma control, discontinue SEREVENT DISKUS and maintain the patient on an inhaled corticosteroid; a long-term asthma control medication.
EUEuropean Union· EMA
1 product
Uses
Seffalair Spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β2 agonists.
How to take
Drug interactions
Known interactions involving Salmeterol. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 557. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLPI187990668 · revised December 27, 2024
- [2]Health Canada (DPD) · 02231129 · revised March 22, 2025
- [3]European Medicines Agency · EMEA/H/C/004881 · revised December 16, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.